CSF1R and glioblastoma: While CSF1R‐targeting strategies are currently being evaluated in patients with GBM (NCT02829723), CSF1R inhibition has also shown some promise in patients with advanced refractory BC bearing brain metastases (Autio et al, 2020), further underscoring the similarities between GBM and BC‐derived brain lesions.